Avid Bioservices Inc (CDMO)

[biopharm]

Steve T. Worsley - new VP Business Development .... after looking at Steves background and past negotiations with Big Pharma.... we are a few steps closer, thats for sure.

http://www.linkedin.com/pub/stephen-worsley/26/b35/271


Chief Business Officer/VP Sales & Licensing
Centrose Pharmaceutical

February 2011 – Present (2 years 11 months)

Biotechnology company focused on developing mAb/Drug Conjugates (ADC's) to extracellular, non-internalizing targets for cancer.

Responsible for all new business development/sales with venture capital, pharmaceutical & biotechnology companies. Primary focus has been in the development of five-year strategic business plan and development/execution of our financing strategy for a $20MM series A VC round. Also lead for all M&A evaluations as well as in and out-licensing for Centrose including long-term alliance strategies with top tier pharmas.

2008-2010 - VP Business Development

Zosano Pharma (a Johnson & Johnson spin out)

Lead negotiator on M&A discussions of Zosano with 5 major WW pharma’s; including selection of investment banker.



2003-2008 Vice President of Business Development
Raven biotechnologies, inc. (acquired by MacroGenics)

Raven identifies antibody drug targets for pairing monoclonal antibodies with specific antigens on the cell surface. Raven utilizes its proprietary stem cell based target identification to find unique and novel targets.

Led and managed collaboration deals including Ravens’s highest value outlicensing deal ever. Companies included; Wyeth, Pfizer, Abbott, ICOS and Immunogen.